HLB Therapeutics Co.,Ltd. Company Description

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally.

It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor.

It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers.

The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021.

HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.

HLB Therapeutics Co.,Ltd.

Country	South Korea
Founded	2000
Industry	Biological Products, Except Diagnostic Substances
Employees	98

Contact Details

Address: Parkview Office Tower Seongnam South Korea
Phone	82 3 1786 7800
Website	hlbtherapeutics.co.kr

Stock Details

Ticker Symbol	115450
Exchange	KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836